The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Changes In Market Value Are Expected For The Non-Proliferative Diabetic Retinopathy Market Over The 2026–2030 Period?
The non-proliferative diabetic retinopathy market size has experienced robust expansion over recent years. Projections indicate an increase in its value from $2.83 billion in 2025 to $3.06 billion by 2026, reflecting a compound annual growth rate (CAGR) of 8.0%. Historically, this expansion has been driven by factors such as the widespread occurrence of diabetes, inadequate understanding of retinal complications, a dependence on traditional laser therapies, limited uptake of intravitreal injections, and an underdeveloped screening infrastructure.
The non-proliferative diabetic retinopathy market is projected to undergo significant expansion in the coming years, with its value expected to reach $3.98 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.8%. This anticipated increase during the forecast period can be attributed to the rising prevalence of diabetic retinopathy, the growing adoption of anti-VEGF and steroid therapies, the expansion of ophthalmology clinics and specialized centers, advancements in retinal imaging technologies, and improvements in patient awareness and early diagnosis programs. Prominent trends for the forecast period include the increasing use of anti-VEGF therapy in NPDR, a rise in the application of intraocular steroid injections, the broader implementation of advanced laser surgery techniques, expanded deployment of vitrectomy procedures, and the progressing integration of AI-powered retinal imaging and diagnosis.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15620&type=smp
Which Key Drivers Are Affecting The Non-Proliferative Diabetic Retinopathy Market Development?
The growing prevalence of diabetes is anticipated to drive the expansion of the non-proliferative diabetic retinopathy market moving forward. Diabetes is a chronic metabolic condition characterized by elevated blood sugar levels, resulting from the pancreas’s inadequate insulin production or the body’s cells becoming resistant to insulin’s effects. Sedentary lifestyles, poor dietary choices, and genetic predispositions are common causes of diabetes. This condition induces non-proliferative diabetic retinopathy through damage to the retina’s blood vessels, mainly due to prolonged exposure to high blood glucose levels, which can lead to vision impairment and potential blindness. For instance, in June 2024, data from the National Health Service, a UK-based government department, indicated that in 2023, the NHS identified over 549,000 additional individuals in England at risk of developing type 2 diabetes. This brought the total number of people with non-diabetic hyperglycemia, or pre-diabetes, registered with a GP to 3,615,330. This marks a substantial increase compared to 3,065,825 in 2022, representing a rise of nearly 20%. Therefore, the increasing prevalence of diabetes is a key driver for the growth of the non-proliferative diabetic retinopathy market.
Which Segments Define The Non-Proliferative Diabetic Retinopathy Market Segment Structure?
The non-proliferative diabetic retinopathy market covered in this report is segmented –
1) By Treatment Type: Anti-Vascular Endothelial Growth Factor (VEGF) Therapy, Intraocular Steroid Injection, Laser Surgery, Vitrectomy
2) By Disease Severity Level: Mild Non-Proliferative Diabetic Retinopathy, Moderate Non-Proliferative Diabetic Retinopathy, Severe Non-Proliferative Diabetic Retinopathy
3) By End-User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Other End-Users
Subsegments:
1) By Anti-Vascular Endothelial Growth Factor (VEGF) Therapy: Bevacizumab (Avastin), Ranibizumab (Lucentis), Aflibercept (Eylea), Pegaptanib (Macugen)
2) By Intraocular Steroid Injection: Triamcinolone Acetonide, Dexamethasone Implant (Ozurdex), Fluocinolone Acetonide Implant (Iluvien)
3) By Laser Surgery: Focal Laser Photocoagulation, Panretinal Photocoagulation
4) By Vitrectomy: Pars Plana Vitrectomy (PPV), Membrane Peeling Vitrectomy, Phaco-Vitrectomy (Combined Cataract And Vitrectomy Surgery)
What Trends Are Transforming The Non-Proliferative Diabetic Retinopathy Market?
Leading entities within the non-proliferative diabetic retinopathy (NPDR) sector are concentrating on creating sophisticated clinical approaches, including initiating Phase 3 registrational trial enrollment, to bolster therapeutic effectiveness, accumulate substantial evidence, and facilitate regulatory clearance for novel NPDR therapies. This enrollment signifies the official commencement and patient allocation into a crucial late-stage clinical study, intended to yield thorough data on efficacy and safety required for securing market authorization for a therapeutic product. An illustrative example is Ocular Therapeutix, a US-based biopharmaceutical firm focused on retinal conditions, which disclosed in November 2025 the initial patient randomization for its HELIOS-3 Phase 3 registrational program, assessing AXPAXLI (OTX-TKI) for NPDR. AXPAXLI represents an experimental bioresorbable intravitreal hydrogel comprising axitinib, a tyrosine kinase inhibitor possessing anti-angiogenic properties, designed to provide prolonged therapeutic effects with reduced injection frequency. Both the HELIOS-3 trial and HELIOS-2 employ an innovative ordinal ≥2-step Diabetic Retinopathy Severity Score (DRSS) improvement as their main outcome measure and enroll participants with non-center-involved diabetic macular edema (non-CI-DME), thereby presenting AXPAXLI as a potentially groundbreaking solution for lasting and efficient NPDR management.
Who Are The Established Players Within The Non-Proliferative Diabetic Retinopathy Market?
Major companies operating in the non-proliferative diabetic retinopathy market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Abbott Laboratories, Novartis AG, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Genentech Inc., Carl Zeiss Meditec AG, ZEISS Group, Santen Pharmaceutical Co. Ltd., Santen Inc., Topcon Corporation, Lumenis Ltd., Alimera Science, Ocular Therapeutix Inc., Acucela Inc., Kowa Company Ltd.
Get The Full Non-Proliferative Diabetic Retinopathy Market Report:
Which Region Holds The Highest Market Share In The Non-Proliferative Diabetic Retinopathy Market?
North America was the largest region in the non-proliferative diabetic retinopathy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-proliferative diabetic retinopathy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Non-Proliferative Diabetic Retinopathy Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Non-Proliferative Diabetic Retinopathy Market 2026, By The Business Research Company
Bladder Cancer Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/bladder-cancer-drugs-global-market-report
Adrenocortical Carcinoma Market Report
https://www.thebusinessresearchcompany.com/report/adrenocortical-carcinoma-global-market-report
Urothelial Carcinoma Treatment Market Report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model